"Progression free Survival" trang 1 - tải miễn phí từ tailieunhanh
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice

Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
10    19    1
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy

A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
11    88    1
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
13    4    1
High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma
10    67    1
Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: Retrospective analysis of cross-sectional data

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: Retrospective analysis of cross-sectional data
7    39    1
Sarcopenia as a risk factor of progression-free survival in patients with metastases: A systematic review and meta-analysis

Sarcopenia as a risk factor of progression-free survival in patients with metastases: A systematic review and meta-analysis
14    4    1
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
5    41    1
The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: A meta-analysis based on 49 articles incorporating 12,120 patients

The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: A meta-analysis based on 49 articles incorporating 12,120 patients
15    8    1
Establishing the quantitative relationship between Lanreotide autogel®, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors

Establishing the quantitative relationship between Lanreotide autogel®, chromogranin A, and progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors
10    54    0
Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival

Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival
7    75    1
PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials

PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials
11    1    1
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
8    55    1
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: Results of the CECOG LaVie trial

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: Results of the CECOG LaVie trial
7    73    1
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)

A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)
6    1    1
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study
8    70    0
MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma

MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma
12    18    1
Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint
11    7    1
Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: A meta-analysis

Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: A meta-analysis
12    83    0
Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis
12    99    1
Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer

Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer
9    53    0